International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.

Slides:



Advertisements
Similar presentations
Project Quality Plans Gillian Sandilands Director of Quality
Advertisements

Radiopharmaceutical Production
Finished Pharmaceutical Product Specifications
Kenya AIDS Vaccine Initiative
1 Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS,
VALIDATION What is the new guidance?. What is a Compliance Policy Guide? Explain FDA policy on regulatory issues CGMP regulations and application commitments.
ICH Q11 – Definisjon av startmaterialer – Fleksibilitet og dokumentasjonskrav Andreas Sundgren LMI 17. april 2012.
Supplier SQM Participation. 2 | MDT Confidential What is SQM? Stands for Supplier Quality Managment –Formally referred to as SPACE and SPICE Is a system.
Batch Reworking and Reprocessing
Breakout C Pharmaceutical Quality System (PQS)
Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.
Determine impurity level in relevant batches1
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.
Quality by Design (QbD) in Product Development
Implementation of Quality-by-Design: ONDQA Initiatives Advisory Committee for Pharmaceutical Science October 5, 2006 Chi-wan Chen, Ph.D. Deputy Director.
MANUFACTURING OF API AND INTERMEDIATES
Quality Risk Management ICH Q9 Annex I: Methods & Tools
Pilot Risk-Ranking Model to Prioritize Manufacturing Sites for GMP Inspections Advisory Committee for Pharmaceutical Science Manufacturing Subcommittee.
World Health Organization
Manufacturing Implementation and the Pharmaceutical Quality System
PAT Validation Working Group Process and Analytical Validation Working Group Arthur H. Kibbe, Ph.D. Chair June 13, 2002.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.
ONDQA Perspective on Post Approval Changes Eric P. Duffy, PhD Director, Division of Post-Market Evaluation, ONDQA, CDER, FDA Public Meeting: Supplements.
1 Revisions to 21 CFR Supplements and Other Changes to an Approved Application PhRMA Perspective FDA Public Meeting – 7 Feb 2007.
Case Study.
Learnings from Pre-approval Joint Inspection of a GSK QbD Product with US-FDA & EMA and the application of Continuous Verification 17 May 2011, Beijing,
Internal Auditing and Outsourcing
Executive summary prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY RISK MANAGEMENT.
World Health Organization
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.
Application of the principles of QbD in vaccines production Andrea Pranti.
Annex I: Methods & Tools prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY.
FDA Regulatory Perspective on Continuous Manufacturing
Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.
Introduction to ISO New and modified requirements.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.
Slide 1 May 2008 Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Mumbai, India Date: May 2008 QUALITY BY DESIGN.
Literature Review and Parts of Proposal
Quality by Design Application of Pharmaceutical QbD for Enhancement of the Solubility and Dissolution of a Class II BCS Drug using Polymeric Surfactants.
Establishing Drug release/Dissolution Specifications – QBD Approach Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER Advisory.
Excipient QbD Concepts to Enhance the Development of Robust Drug Products Priscilla S. Zawislak Global Regulatory Affairs Manager - Ashland Inc. Chair.
1 Supplements and Other Changes to an Approved Application By: Richard J. Stec Jr., Ph.D. February 7, 2007.
PRODUCT TRANSFER.
NIPTE-FDA Collaborative Case Study On Model-based Design Space Development Across Scales & with Stability Considerations Preliminary Design Space 1.
Quality by Design (QbD) Myth : An expensive development tool ! Fact : A tool that makes product development and commercial scale manufacturing simple !
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.
BioTx Pharmaceutical Sciences Movement within the design space with a robust control strategy Jon Coffman, Ph.D. Principal Engineer III BioTherapeutic.
Molecule-to-Market-Place Quality
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
Breakout D Quality Risk Management
Satish Mallya January 20-22, |1 | 2-3. Pharmaceutical Development Satish Mallya Quality Workshop, Copenhagen May 18-21, 2014 May 18-21,2014.
General Aspects of Quality assessment of multisource interchangeable medicines Rutendo Kuwana Technical Officer, WHO, Geneva Training workshop: Assessment.
1 Views expressed in this presentation are my own, and do not necessarily reflect official FDA opinions/policy Views expressed in this presentation are.
CDER / Office of Compliance ACPS October 5, 2006 Joseph C. Famulare Acting Deputy Director Office of Compliance CDER / FDA.
INFOMGP Student names and numbers Papers’ references Title.
开发报批美国 FDA 的仿制药 与相关问题探讨 上海复星普适医药科技有限公司何平. 内容提要 开发仿制药的重要性和机遇 开发仿制药的重要性和机遇 开发仿制药的挑战 开发仿制药的挑战 申报仿制药的分类 申报仿制药的分类 仿制药研发团队 仿制药研发团队 仿制药的研发过程 仿制药的研发过程 QbD 在制剂开发中怎么体现.
QbD Technologies: Workshop for Risks Management Incorporating Risk Management for Technology Transfer.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.
Organization and Implementation of a National Regulatory Program for the Control of Radiation Sources Program Performance Criteria.
WORKSHOP ON ACCREDITATION OF BODIES CERTIFYING MEDICAL DEVICES INT MARKET TOPIC 6 CH 5 ISO MANAGEMENT RESPONSIBILITY Philippe Bauwin Medical.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.
In the name of God. Common Technical Document On Biotech.
Quality by design (Qbd)
QUALITY BY DESIGN Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Mumbai, India Date: May 2008.
Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER.
Quality by Design.
Radiopharmaceutical Production
Manufacture of Sterile Medicinal Products: ‘Annex 1’ - DRAFT
Presentation transcript:

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10 Breakout A Design Space

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 2 Breakout A: Design Space © ICH, November 2010 Disclaimer The information within this presentation is based on the ICH Q-IWG members expertise and experience, and represents the views of the ICH Q-IWG members for the purposes of a training workshop.

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 3 Breakout A: Design Space © ICH, November 2010 Introduction Structure of this session - Discussion of key messages on Design Space - Examples from the Case Study - Wrap up - Feedback on barriers to implementation - Feedback on issues where further clarification is required - Breakout report

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 4 Breakout A: Design Space © ICH, November 2010 Introduction There are no regulatory requirements to have a Design Space Quality Risk Management approaches need to be considered to ensure the robustness of the Design Space Design space can illustrate understanding of parameter interactions and provides manufacturing flexibility - Proven acceptable range alone is not a design space Design space can include critical and non-critical parameters Design space should be verified and opperational at full scale - No requirement to develop a design space at the full manufacturing scale - Many options exist for how (and where) to present a design space

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 5 Breakout A: Design Space © ICH, November 2010 Training Objectives Design Space development - Steps in Development of Design Space - Prior knowledge - QRM - DOE & modeling - Process Parameter and Quality Attribute as factors in Design Space development Implementation of Design Space Presentation of Design Space in regulatory submission

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 6 Breakout A: Design Space © ICH, November 2010 Steps in Development of Design Space Consider QTPP in establishing the Design Space Initial determination of CQAs Assess prior knowledge to understand variables and their impact - Scientific principles & historical experience Perform initial risk assessment of manufacturing process relative to CQAs to identify the high risk manufacturing steps (->CPPs) Conduct Design of Experiments (DoE) Evaluate experimental data Conduct additional experiments/analyses as needed

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 7 Breakout A: Design Space © ICH, November 2010 QbD Story per Unit Operation Process Variables Design of Experiments Quality Risk Management Illustrative Examples of Unit Operations: QTPP & CQAs Design Space Control Strategy Batch Release Compression Real Time Release testing (Assay, CU, Dissolution) Blending API Crystallization

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 8 Breakout A: Design Space © ICH, November 2010 DS development - Prior knowledge Key messages - Prior knowledge may include : - internal knowledge from development and manufacturing - External knowledge: scientific and technical publications (including literature and peer-reviewed publications) - Citation in filing: regulatory filings, internal company report or notebook, literature reference - No citation necessary if well known and accepted by scientific community

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 9 Breakout A: Design Space © ICH, November 2010 DS development - Prior knowledge What might be applicable sources of Prior Knowledge ? Identify other type of prior knowledge that can be used in DS development Example from Case Study : Crystallization of the drug substance - Particle size control needed during crystallization - Prior knowledge/1 st principles shows that other unit operations (Coupling reaction, aqueous workup, filtration and drying) have low risk of affecting purity or PSD. > Knowledge from prior filings > Knowledge from lab / piloting data, including data from other compounds using similar “platform” technologies > First principles knowledge from texts/papers/other respected sources

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 10 Breakout A: Design Space © ICH, November 2010 DS development - QRM Risk assessment is based on prior knowledge and relevant experience for the product and manufacturing process - Gaps in knowledge could be addressed by further experimentation - Assignments of risk level must be appropriately justified Risk assessments/control will iterate as relevant new information becomes available - Final iteration shows control of risks to an acceptable level

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 11 Breakout A: Design Space © ICH, November 2010 DS development - QRM Training questions - If the risk acceptance criteria (conclusions) are different than scientific theory/prior knowledge would indicate, then is further explanation provided to justify unexpected conclusions? - If there are gaps in the information then what would the plan be to make adjustments to further reduce risk?

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 12 Breakout A: Design Space © ICH, November 2010 Illustration from the Case Study - Risk Assessment for PSD Control To be investigated in DOE Detailed working documents like this would likely not be included in the submission Case Study Example

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 13 Breakout A: Design Space © ICH, November 2010 DS development – DOE & Modeling Target the desired quality attribute range from QTPP Determination of edge of failure is not required Modeling is not required to develop a Design Space Models need to be verified, updated and maintained

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 14 Breakout A: Design Space © ICH, November 2010 DS development – DOE & Modeling - Does the DOE results, as presented in the case study, provide sufficient information to define a design space? - Describe which parameters are addressed by univariate vs. multivariate DOEs and how these are factored into the design space - Model implementation: Describe how variability due to the process operations and/or analytical method is considered in use of the model - Describe the process for maintenance & updating of the model

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 15 Breakout A: Design Space © ICH, November 2010 DS development – Process parameter & quality attributes - Design space presentation in the submission could include critical and non-critical parameters - Critical parameter ranges/model are considered a regulatory commitment and non-critical parameter ranges support the review of the filing - Critical parameter changes within design space are handled by the Quality System and changes outside the design space need appropriate regulatory notification - Non-critical parameters would be managed by Quality System

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 16 Breakout A: Design Space © ICH, November 2010 DS development – Process parameter & quality attributes Illustration & training questions - Has the model for PSD Control (next slide) been demonstrated to be scale and equipment independent? - Is a mathematical model always needed to have a design space? - How to evaluate the impact of changing non-critical process parameters when included in the design space ? - Technical evaluation of a change of non-critical is the same scientific principle as for critical

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 17 Breakout A: Design Space © ICH, November 2010 Illustration from case study : QTPP and CQAs Dosage form and strength Immediate release tablet containing 30 mg of active ingredient. Specifications to assure safety and efficacy during shelf-life Assay, Uniformity of Dosage Unit (content uniformity) and dissolution. Description and hardnessRobust tablet able to withstand transport and handling. AppearanceFilm-coated tablet with a suitable size to aid patient acceptability and compliance. Total tablet weight containing 30 mg of active ingredient is 100 mg with a diameter of 6 mm. Drug Product CQAs Assay Content Uniformity Dissolution Tablet Mechanical Strength CQAs derived using Prior Knowledge (e.g. previous experience of developing tablets) CQAs may be ranked using quality risk assessment. QTPP

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 18 Breakout A: Design Space © ICH, November 2010 API Crystallization: Design Space & Control Strategy

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 19 Breakout A: Design Space © ICH, November 2010 Implementation of Design Space What PQS element need to be considered ? How DS is captured in batch documentation and batch release ? How DS knowledge used in managing changes in the manufacturing process? What information would be transmitted to the manufacturing site?

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 20 Breakout A: Design Space © ICH, November 2010 Presentation of Design Space in regulatory submission Design Space need to be clearly presented and justified in regulatory submission - Design Space need to be described in sufficient details in regulatory filing - Description could include critical and non critical parameters to assure complete understanding - Designation of criticality need to be justified in regulatory submission based on QRM and/or experimental results

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 21 Breakout A: Design Space © ICH, November 2010 Presentation of design space in regulatory submission What is needed in the manufacturing process description in the filing to demonstrate the implementation of the Design Space? What is the appropriate level of detail to present DOE and it’s conclusions in regulatory submissions ?

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 22 Breakout A: Design Space © ICH, November 2010 Large square shows the ranges tested in the DOE Red area shows points of failure Green area shows points of success. In the idealized example at left, the oval represents the full design space. It would need to be represented by an equation. Alternatively, the design space can be represented as the green rectangle by using ranges - a portion of the design space is not utilized, but the benefit is in the simplicity of the representation Seed wt% Illustration from the case study : Options for Depicting a Design Space

ICH Quality Implementation Working Group - Integrated Implementation Training Workshop slide 23 Breakout A: Design Space © ICH, November 2010 Acknowledgement This presentation has been developed by members of the ICH Quality Implementation Working Group (Q-IWG) Jean-Louis Robert (rapporteur) Diana Amador-Toro Robert G. Baum Nicholas Cappuccino David Cockburn Georges France Richard L. Friedman Nigel Hamilton Hirotada Nagai Yukio Hiyama Fusashi Ishikawa Takao Kiyohara Urs Kopp Akira Kusai Yoshihiro Matsuda Motoaki Mitsuki Elaine Morefield Jacques Morénas Masatoshi Morisue Markus-Peter Müller Tamiji Nakanishi Moheb Nasr Kazuhiro Okochi Anthony Ridgway Rachael Roehrig Stephan Rönninger Swroop Sahota Hideki Sasaki Tetsuhito Takarada Shigeki Tamura Krishnan Tirunellai Mats Welin Jean M. Wyvratt A J van Zyl